Healthcare
Live Price
Offline$10.19
+1.90% today
1Y Change
-2.82%
Window
Jun 23, 2025 → Jun 8, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Replimune Group, Inc. (REPL) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $10.19 and down 2.8% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +5.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +5.2%, free cash flow -4.1% with operating margin 0.0% and ROIC -113.2%. Stock Foundry combines REPL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REPL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REPL Max Drawdown
-86.54%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REPL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$80.9M
+31.5% YoY
Free Cash Flow
-$63.8M
+24.5% YoY
Revenue Growth
+0.0%
EPS Growth
+5.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -5M | -4M |
| Operating Income | -262M | -235M | -177M | -121M | -83M |
| EBITDA | -254M | -228M | -172M | -114M | -76M |
| Net Income | -247M | -216M | -174M | -118M | -81M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 111M | 74M | 147M | 106M | 183M |
| Total Assets | 551M | 488M | 647M | 461M | 543M |
| Total Liabilities | 135M | 113M | 91M | 50M | 44M |
| Shareholder Equity | 416M | 375M | 555M | 411M | 499M |
| Total Debt | 76M | 76M | 61M | 33M | 33M |
| Net Debt | -35M | 1M | -86M | -73M | -149M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
61M
+25.3% YoY
Capital Expenditures
2M
-2.4% YoY
Free Cash Flow
64M
+24.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-102.7%
Debt / Equity
0.37x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.